RA patients with an inadequate response to adalimumab, in the presence of sufficient/high ADA drug levels, benefit 33% less from switching to another TNF inhibitor, etanercept. Data 449 RA patients in the Reade Rheumatology Registry https://t.co/uBzF8D9KpA